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Prognostic Utility of Microvolt
-Wave Alternans in Risk Stratification
f Patients With Ischemic Cardiomyopathy
heodore Chow, MD, FACC,* Dean J. Kereiakes, MD, FACC,* Cheryl Bartone, RN,* Terri Booth, RN,*
dward J. Schloss, MD, FACC,* Theodore Waller, MD, FACC,* Eugene S. Chung, MD,*
antosh Menon, MD,* Brahmajee K. Nallamothu, MD, MPH,† Paul S. Chan, MD, MSC†
incinnati, Ohio; and Ann Arbor, Michigan
OBJECTIVES The purpose of this study was to assess if microvolt T-wave alternans (MTWA) is an
independent predictor of mortality in patients with ischemic cardiomyopathy.
BACKGROUND Microvolt T-wave alternans has been proposed as an effective tool for identifying high-risk
patients with ischemic cardiomyopathy who are likely to benefit from implantable
cardioverter-defibrillator (ICD) therapy. However, earlier studies have been limited in their
ability to control for baseline differences between MTWA-negative and -non-negative
(positive and indeterminate) patients.
METHODS We enrolled 768 consecutive patients with ischemic cardiomyopathy (left ventricular ejection
fraction 35%) and no prior history of ventricular arrhythmia. All patients underwent
baseline MTWA testing and were classified as MTWA negative or non-negative. Multiva-
riable Cox regression analyses, stratified by ICD status, were used to determine the
association between MTWA testing and mortality after adjusting for demographic, clinical,
and treatment differences between MTWA-negative and -non-negative patients.
RESULTS We identified 514 (67%) patients with a non-negative MTWA test. After multivariable
adjustment, a non-negative MTWA test was associated with a significantly higher risk for
all-cause (stratified hazard ratio [HR]  2.24 [95% confidence interval 1.34 to 3.75]; p 
0.002) and arrhythmic mortality (stratified HR  2.29 [1.00 to 5.24]; p  0.049) but not for
nonarrhythmic mortality (stratified HR  1.77 [0.84 to 3.74]; p  0.13). In subgroup
analyses, a non-negative MTWA test was also associated with a higher risk for all-cause
mortality in patients with ejection fractions 30% (stratified HR  2.10 [1.18 to 3.73]; p 
0.01) and after excluding those with indeterminate MTWA tests (stratified HR 2.08 [1.18
to 3.66]; p  0.01).
CONCLUSIONS Microvolt T-wave alternans is a strong and independent predictor of all-cause and arrhythmic
mortality in patients with ischemic cardiomyopathy. (J Am Coll Cardiol 2006;47:1820–7)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.079© 2006 by the American College of Cardiology Foundation
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oudden cardiac death (SCD) is the leading cause of mor-
ality in patients with ischemic heart disease and left
entricular dysfunction (1). The second Multicenter Auto-
atic Defibrillator Implantation Trial (MADIT-II) and the
udden Cardiac Death in Heart Failure Trial (SCD-HeFT)
ave shown that implantable cardioverter-defibrillators
ICDs) reduce mortality in patients with ischemic heart
isease and left ventricular ejection fractions (LVEF)30%
nd 35%, respectively (2,3). Although ICD implantation
ay be cost effective overall (4–7), widespread use of ICDs
s likely to be constrained by fixed health care budgets.
urther risk stratification of the pool of patients considered
ligible for ICDs would have broad implications for the
ealthcare system.
Microvolt T-wave alternans (MTWA) involves the de-
ection of every-other-beat alternations in T-wave morphol-
From *The Lindner Clinical Trial Center at the Christ Hospital and the Ohio
eart & Vascular Center, Cincinnati, Ohio; and the †VA Health Services Research
Development and University of Michigan Medical School, Ann Arbor, Michigan.
his study was funded in part by Medtronic. Dr. Chan is supported by a National
nstitutes of Health Cardiovascular Multidisciplinary Research Training Grant and by
he Ruth L. Kirchstein Research Service Award.v
Manuscript received August 16, 2005; revised manuscript received October 25,
005, accepted November 1, 2005.gy. These alternations are thought to represent abnormal-
ties in intracellular calcium handling that may predispose
atients to ventricular tachyarrhythmias (8–10). Earlier
tudies have suggested that MTWA may be a useful,
oninvasive method for discriminating between patients
ith ischemic cardiomyopathy that are at low and high risk
or SCD (11,12). Although provocative, these studies were
rimarily limited in their ability to adjust for baseline
ifferences in clinical characteristics (such as age and LVEF)
etween patients who tested MTWA negative and non-
egative (positive and indeterminate) (13). Without adjust-
ng for such baseline differences, it is unclear whether
TWA adds additional prognostic value over traditional
linical characteristics that are often associated with SCD
13,14).
We therefore evaluated whether MTWA was an inde-
endent predictor of mortality in patients with ischemic
ardiomyopathy after adjusting for demographics and clin-
cal characteristics including ICD status, age, LVEF, pro-
onged QRS duration, clinical comorbidities, and medica-
ion treatment. We also determined if the prognostic utility
f MTWA was related to its ability to predict arrhythmic
ersus nonarrhythmic mortality.
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tudy population. A multicenter prospective cohort com-
osed of four outpatient cardiology clinics was developed
nd coordinated by the Ohio Heart and Vascular Center
nd the Lindner Clinical Trials Center, Cincinnati, Ohio.
onsecutive patients with varying LVEF were enrolled be-
ween March 2001 and June 2004 during their MTWA test
index date). For this study, we included patients with ischemic
eart disease (defined as cardiac catheterization with 70%
tenosis in at least one coronary vessel, documented myo-
ardial infarction, or a history of coronary revascularization)
nd LVEF 35%. Patients also had to be at least 21 years
ld, have no history of a prior ventricular arrhythmic event,
nd be in sinus rhythm at the time of MTWA testing. All
atients gave informed consent to registry enrollment and
ollow-up. The study was approved by the institutional
eview board at The Christ Hospital, Cincinnati, Ohio.
TWA testing protocol. At study enrollment, all patients
nderwent baseline MTWA testing by treadmill exercise
Heartwave System, Cambridge Heart, Bedford, Massachu-
etts) with elevation of the heart rate to a target level of 120
eats/min. Beta-blockers and non-dihydropyridine calcium-
hannel blockers were withheld for 24 h before the test.
ll MTWA tests were interpreted according to standard
riteria by an expert reader blinded to patient characteristics
nd clinical outcomes (15). A positive MTWA test was
efined as sustained alternans with an onset heart rate of
110 beats/min. A negative MTWA test was defined as
he absence of criteria for a positive test with a maximum
eart rate of 105 beats/min. All other tests were classified
s indeterminate. Based on earlier studies (11,12,14,16), we
lassified both indeterminate and positive tests as “non-
egative” during statistical analyses, but also examined
TWA-positive and -indeteminate results separately dur-
ng secondary analyses.
ata collection. We collected patient data on demo-
raphic and clinical characteristics at the time of enrollment,
ncluding: age, gender, LVEF, QRS duration 120 ms,
iabetes mellitus, hypertension, symptomatic heart failure,
hronic obstructive pulmonary disease, chronic renal insuf-
ciency, peripheral vascular disease, and history of myocar-
ial infarction, stroke, transient ischemic attack, atrial
Abbreviations and Acronyms
CI  confidence interval
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
LVEF  left ventricular ejection fraction
MADIT-II  second Multicenter Automatic
Defibrillator Implantation Trial
MTWA  microvolt T-wave alternans
SCD  sudden cardiac death
SCD-HeFT  Sudden Cardiac Death in Heart Failure
Trialbrillation, unexplained syncope, or revascularization ther- spy. Data on baseline medication use of aspirin, angiotensin-
onverting enzyme inhibitor, angiotensin-receptor blocker,
eta-blocker, digoxin, diuretic, class I or III antiarrhythmic
gent, statin, and spironolactone were also obtained.
We also collected data on diagnostic testing with Holter
onitoring and ICD implantation. We defined nonsus-
ained ventricular tachycardia on Holter monitoring as
100 beats/min for three or more consecutive beats and
30 s. The decision for ICD implantation, including the
ype of device and programming, was at the discretion of the
reating physician.
rimary end points and follow-up. The primary end point
or the study was all-cause mortality. Secondary endpoints
ncluded cause-specific mortality, individual comparisons
etween the MTWA-positive, -indeterminate, and
negative groups, and the delivery of appropriate ICD
hocks in patients with ICDs. Cause-specific mortality was
etermined by two study team members blinded to the
ecedent’s MTWA status and was classified as arrhythmic
r nonarrhythmic in etiology using a modified Hinkle-
haler system (17). Arrhythmic deaths included unwit-
essed deaths (if stable when last observed before death),
itnessed instantaneous deaths, and deaths as a sequelae of
ardiac arrest. In patients with ICDs, ICD shocks were
eviewed by a physician blinded to MTWA status to
etermine their appropriateness. Clinical follow-up for end
oints was achieved by quarterly office visits, telephone
ontact with patients, review of office charts, and by an
nnual query of the National Death Index (18,19).
ata analysis. Because ICDs have been shown to be
fficacious in reducing mortality in this population, stratified
ox proportional hazards analyses by ICD status were
lanned for the study outcomes if no significant interaction
xisted between the ICD and MTWA variables. The
ationale for stratified analyses was to ensure appropriate
djustment of a variable known to significantly affect mor-
ality in patients with ischemic cardiomyopathy (20).
Patients in the study cohort were first divided into those
ith and without ICDs. Baseline characteristics between
hose who tested MTWA negative and non-negative in the
CD and non-ICD groups were compared using Student
tests for continuous variables and chi-square tests for
ategorical variables. Survival curves between the MTWA-
egative and -non-negative groups stratified by ICD status
ere constructed using Kaplan-Meier estimates, and the
nadjusted relationship of MTWA testing with mortality
as assessed with the stratified log-rank test.
Stratified multivariable Cox proportional hazards model-
ng was then performed to assess the independent relation-
hip of MTWA with event-free survival. Candidate vari-
bles included age, gender, LVEF, QRS duration120 ms,
linical comorbid conditions (diabetes mellitus, hyperten-
ion, symptomatic heart failure, chronic obstructive pulmo-
ary disease, chronic renal insufficiency, peripheral vascular
isease, and history of myocardial infarction, stroke, tran-
ient ischemic attack, atrial fibrillation, unexplained syn-
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ent (aspirin, angiotensin-converting enzyme inhibitor or
ngiotensin-receptor blocker, beta-blocker, digoxin, di-
retic, class I or III antiarrhythmic agent, statin, and
pironolactone). Covariates associated with survival in uni-
ariate analyses (p  0.10) were entered in a stepwise
ashion based on a significance level of p  0.05. Age and
VEF were included in the final model regardless of the
evel of significance. Potential two-way interactions between
ovariates were also examined, including an interaction
etween MTWA result and ICD status to determine if the
azard ratio for all-cause mortality with MTWA differed by
CD group and to ensure that the stratified analysis would
e appropriate (20).
Additional analyses were performed to assess whether
here were important differences in hazard ratios across
respecified subgroups in the cohort. Consistent with the
ADIT-II trial inclusion criteria, we performed stratified
ultivariable analyses for only those patients with LVEF
30%. To determine how the inclusion of patients with
ndeterminate MTWA results in the MTWA-non-negative
roup affected our results, we repeated our analyses com-
aring only those patients who tested MTWA positive or
ndeterminate with those who tested MTWA negative.
able 1. Baseline Characteristics of Study Cohort Stratified by D
Covariates
Without ICDs
MTWA
Negative
(n  179)
MTWA
Non-Negativ
(n  197)
ean survival, days  SD 573.5  312 540  314
ge, yrs 65.2  11.0 69.6  10.7
ender, % male 81.0 76.7
VEF, % 29.3  5.5 27.3  6.7
olter NSVT, % (n) 3.7 (108) 21.6 (134)
RS 120 ms, % 23.0 28.9
yocardial infarction, % 86.0 78.8
HF, % 63.7 70.0
istory of atrial fibrillation, % 12.9 16.8
ABG, % 55.9 54.8
TCA, % 53.1 46.7
iabetes mellitus, % 34.6 42.1
ypertension, % 34.6 35.5
OPD, % 3.9 8.1
VD, % 6.7 3.1
troke/TIA, % 12.3 18.3
enal insufficiency, % 3.4 3.0
yncope, % 16.2 16.8
edications
Aspirin, % 76.0 76.7
ACE-I or ARB, % 84.4 82.2
Beta-blocker, % 83.2 76.1
Aldactone, % 12.3 15.2
Statin, % 57.7 46.8
Digoxin, % 20.7 33.0
Diuretic, % 60.3 65.0
Class I antiarrhythmic, % 0.0 1.0
Class III antiarrhythmic, % 7.8 9.1
CE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin-receptor bl
hronic obstructive pulmonary disease; ICD  implantable cardioverter-defibrillator; LVEF
onsustained ventricular tachycardia; PTCA  percutaneous transluminal coronary angiopinally, for the subgroup of patients with Holter monitor
est results, stratified Cox proportional hazards models were
onstructed with the addition of nonsustained ventricular
achycardia to the candidate variables.
Finally, we also assessed whether MTWA was an indepen-
ent predictor of arrhythmic mortality, nonarrhythmic mortal-
ty, and appropriate ICD shock therapy (in the ICD group
nly). In all models, the assumption of proportionality for the
ox proportional hazards models was visually assessed with
og-log (survival) versus log (survival time) to ensure parallel-
sm. All statistical analyses were performed with SAS version
.2 (SAS Institute, Cary, North Carolina).
ESULTS
aseline characteristics and unadjusted analyses. Of the
68 patients, 514 (67%) had a non-negative MTWA test.
ean follow-up for the entire cohort was 18  10 months,
nd was similar across MTWA subgroups. Table 1 depicts
aseline characteristics of the study cohort stratified by ICD
tatus. When compared with patients who tested MTWA
egative, patients without ICDs with non-negative
TWA results were significantly older, had lower ejection
ractions, were more likely to have evidence of nonsustained
illator Status
With ICDs
p Value
MTWA
Negative
(n  75)
MTWA
Non-Negative
(n  317) p Value
540.9  332 553.7  289
.001 64.7  10.8 67.4  9.6 0.03
0.30 81.3 87.1 0.20
0.001 26.9  5.9 26.1  6.0 0.30
.001 22.0 (59) 25.4 (213) 0.60
0.29 36.5 39.0 0.74
0.06 88.0 88.3 0.94
0.19 80.0 75.4 0.40
0.29 18.7 14.2 0.33
0.84 54.7 57.4 0.67
0.22 54.7 52.1 0.68
0.14 26.7 39.1 0.04
0.86 37.3 36.0 0.82
0.08 6.7 8.5 0.60
0.10 2.7 5.7 0.19
0.11 8.0 16.4 0.07
0.87 1.3 2.5 0.54
0.89 16.0 14.8 0.80
0.88 81.3 75.4 0.28
0.58 90.7 84.5 0.12
0.09 84.0 84.9 0.85
0.41 26.7 17.4 0.07
0.03 69.3 64.7 0.45
0.007 32.0 44.2 0.06
0.35 72.0 65.9 0.32
0.16 2.7 0.3 0.22
0.65 6.7 8.8 0.54
CABG  coronary artery bypass graft; CHF  congestive heart failure; COPD efibr
e
ocker;
 left ventricular ejection fraction; MTWA  microvolt T-wave alternans; NSVT 
lasty; PVD  peripheral vascular disease; TIA  transient ischemic attack.
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igoxin at a higher rate, were less likely to be on statins, and
ere less likely to have a history of myocardial infarction.
atients with ICDs with non-negative MTWA were sig-
ificantly older and more likely to have diabetes mellitus.
In the non-ICD group, there were 58 deaths (MTWA
egative: 15 [8.4%]; MTWA non-negative: 43 [21.8%]), of
hich 28 were arrhythmic deaths (MTWA negative: 6 [3.4%];
TWA non-negative: 22 [11.2%]). In the ICD group, there
ere 41 deaths (MTWA negative: 6 [8.0%]; MTWA non-
egative: 35 [11.0%]), of which 14 were arrhythmic deaths
MTWA negative: 3 [4.0%]; MTWA non-negative: 11
3.5%]) (Table 2). There were also a total of 26 appropriate
CD therapies not associated with death in the ICD group.
Kaplan-Meier event-free survival curves for all-cause
ortality comparing those who tested MTWA negative and
on-negative, stratified by ICD status, are shown in Figure 1.
vent-free survival for MTWA-negative patients was sig-
ificantly higher than for MTWA-non-negative patients
stratified log-rank statistic  13.50; p  0.0002).
Table 2. Summary Table of End Points Stratifi
Outcomes
Non
MTWA
Negative
(n  179)
Total deaths (%) 15 (8.4%)
Arrhythmic deaths (%) 6 (3.4%)
Nonarrhythmic deaths (%) 9 (5.0%)
Appropriate ICD shocks (%) —
Data for the primary end point of all-cause mortality and for t
ICD shocks are provided. Discrepancies are due to round-o
Abbreviations as in Table 1.
Table 3. Summary Table of Unadjusted and A
Predicting Mortality
Unadjus
Hazard Ratio
Main analysis
Mortality
All-cause 2.51 (1.51–
Arrhythmic 2.93 (1.33–
Nonarrhythmic 2.24 (1.16–
Secondary outcome
LVEF
30% (n  537) 2.35 (1.26–
31%–35% (n  231) 3.37 (1.09–
Nondefibrillator (n  376) 2.77 (1.54–
Defibrillator (n  392)
Death 1.86 (0.72–
Shocks 3.77 (0.89–
Death  shocks 2.40 (1.09–
Stratified (by ICD status) results are provided for all-cause a
models include age, gender, LVEF, QRS duration 120 m
symptomatic heart failure, chronic obstructive pulmonary di
history of myocardial infarction, stroke, transient ischemic a
therapy), and medication treatment (aspirin, angiotensin
beta-blocker, digoxin, diuretic, class I or III antiarrhythmic a
ejection fraction 35% except where indicated. All secondary anal
CI  confidence interval; other abbreviations as in Table 1.ultivariable Cox proportional hazard models. ALL-
AUSE MORTALITY. Patients with a non-negative MTWA
esult had a higher risk of all-cause mortality after multiva-
iable adjustment (stratified hazard ratio [HR]2.24 [95%
onfidence interval [CI] 1.34 to 3.75]; p 0.002) (Table 3).
lthough a number of interaction terms were examined,
one reached statistical significance. Importantly, an HR
ssociated with a non-negative MTWA test did not signif-
cantly differ by ICD status (p  0.47 for interaction
etween ICD status and MTWA test result). When the
esults were examined separately for the ICD and non-ICD
roups, the hazard ratios for a MTWA-non-negative test
ere not much different (HR  1.79 for ICD patients and
.27 for non-ICD patients), but the findings in the ICD
roup were not statistically significant. Results were equally
obust when only patients with LVEF 30% were consid-
red (n  537; stratified HR  2.10 [95% CI 1.18 to 3.73]
or a non-negative MTWA test; p  0.01) (Table 3). A
on-negative MTWA test also showed a trend toward
igher mortality among patients with LVEF between 31%
y Defibrillator Status
ICD
MTWA
n-Negative
n  197)
MTWA
Negative
(n  75)
MTWA
Non-Negative
(n  317)
3 (21.8%) 6 (8.0%) 35 (11.0%)
2 (11.2%) 3 (4.0%) 11 (3.5%)
1 (10.7%) 3 (4.0%) 24 (7.6%)
— 2 (2.7%) 24 (7.6%)
ondary end points of cause-specific mortality and appropriate
.
ed Stratified Cox Models for MTWA in
CI)
Adjusted: All Variables
Hazard Ratio (95% CI) p Value
2.24 (1.34–3.75) 0.002
2.29 (1.00–5.24) 0.049
1.77 (0.84–3.74) 0.13
2.10 (1.18–3.73) 0.012
) 2.99 (0.93–9.68) 0.067
2.27 (1.22–4.24) 0.001
1.79 (0.66–4.86) 0.25
) 3.74 (0.88–15.91) 0.07
2.42 (1.07–5.48) 0.035
use-specific mortality. Candidate variables for adjusted Cox
ical comorbid conditions (diabetes mellitus, hypertension,
chronic renal insufficiency, peripheral vascular disease, and
atrial fibrillation, unexplained syncope, or revascularization
rting enzyme inhibitor or angiotensin receptor blocker,
tatin, and spironolactone). All analyses are for patients withed b
-ICD
No
(
4
2
2
he secdjust
ted
(95%
4.15)
6.46)
4.31)
4.31)
10.43
5.00)
4.78)
16.09
5.28)
nd ca
s, clin
sease,
ttack,
-conve
gent, syses are for all-cause mortality, except where indicated.
a
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.68]; p  0.067). Finally, when we examined only those
atients who also had Holter tests performed, a non-
egative MTWA remained a significant predictor after
djusting for the presence of nonsustained ventricular
achycardia in addition to other candidate variables (n 
14; stratified HR  2.31 [95% CI 1.28 to 4.17]; p 
Figure 1. Kaplan-Meier survival curves for all-cause mor.005). pAUSE-SPECIFIC MORTALITY AND APPROPRIATE ICD
HOCKS. Stratified Cox proportional hazards analyses
ound that a non-negative MTWA test was an independent
redictor of arrhythmic mortality (stratified HR  2.29
95% CI 1.00 to 5.24]; p  0.049). However, no significant
elationship with MTWA status was found for nonarrhyth-
ic mortality (stratified HR  1.77 [95% CI 0.84 to 3.74];
for the study population stratified by defibrillator status. 0.13) (Table 3). In patients with ICDs, a non-negative
M
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CD shocks not associated with death (HR 3.79 [95% CI
.88 to 15.91]; p  0.07). When a combined end point of
ll-cause mortality and ICD shocks was assessed, a non-
egative MTWA was an independent predictor of event-
ree survival in the ICD group (HR 2.42 [95% CI 1.07 to
.48]; p  0.035).
OMPARISONS OF MTWA-POSITIVE OR -INDETERMINATE
ATIENTSWITHMTWA-NEGATIVE PATIENTS. Of those clas-
ified as MTWA non-negative (n 514), 159 testedMTWA
ndeterminate. Reasons for an indeterminate test included
requent ectopy (n  63 [40%]), inability to reach adequate
eart rate for MTWA assessment (n  59 [37%]), excessive
ackground noise (n  22 [14%]), and unsustained alternans
n  15 [9%]). When the analysis was limited to only those
atients who tested MTWA positive or negative (i.e., indeter-
inate MTWA patients excluded), a positive MTWA was
ssociated with higher all-cause mortality (n  609; stratified
R  2.08 [95% CI 1.18 to 3.66]; p 0.01) and a trend
oward higher arrhythmic mortality (stratified HR  2.03
95% CI 0.83 to 4.97]; p  0.13) (Table 4). Similarly,
omparisons between patients who tested MTWA indetermi-
ate and negative showed that an indeterminate MTWA was
ssociated with higher rates of all-cause (n  413; stratified
R  2.78 [95% CI 1.55 to 4.99]; p  0.0006) and
rrhythmic (stratified HR  3.62 [95% CI 1.44 to 9.13]; p 
able 4. Mortality Comparisons Between MTWA Positive, Neg
Outcomes
Non-ICD
Negative
(n  179)
Positive
(n  121)
I
otal deaths (%) 15 (8.3%) 26 (21.5%)
Arrhythmic (%) 6 (3.4%) 13 (10.7%)
Nonarrhythmic (%) 9 (5.0%) 13 (10.7%)
Unadjusted
Hazard Ratio (95% CI)
ortality
All-cause 2.26 (1.30–3.92)
Arrhythmic 2.50 (1.05–5.97)
Nonarrhythmic 2.11 (1.04–4.30)
ortality
All-cause 2.97 (1.67–5.20)
Arrhythmic 3.50 (1.46–8.38)
Nonarrhythmic 2.67 (1.27–5.62)
ortality
All-cause 0.65 (0.41–1.02)
Arrhythmic 0.53 (0.27–1.07)
Nonarrhythmic 0.73 (0.41–1.31)
wo-way comparisons between the MTWA groups using multivariable Cox regressio
redictors of mortality compared to a MTWA negative result. No significant diff
ndeterminate.
Abbreviations as in Tables 1 and 3..006) mortality. However, comparisons between patients who 1ested MTWA positive and indeterminate did not show
ignificant differences in all-cause or cause-specific mortality.
ISCUSSION
his study is the largest series to date to examine the
redictive ability of MTWA to risk-stratify patients with
schemic heart disease and left ventricular dysfunction. We
ound that patients with ischemic cardiomyopathy and a
on-negative MTWA test result have a more than two-fold
igher risk of all-cause mortality when compared with
atients with a negative MTWA result. Although one could
rgue that the presence of MTWA may simply represent a
omposite risk profile from a patient’s joint distribution of
linical and comorbid conditions, our study found that
TWA remained an independent predictor even after
ontrolling for demographics, clinical comorbidities, ICD
tatus, and medication treatment. Importantly, we also
emonstrated that the increased risk associated with a
on-negative MTWA result is mediated primarily through
igher rates of arrhythmic mortality.
Prior studies of MTWA testing in patients with ischemic
ardiomyopathy have reported more impressive results than
he adjusted hazard ratio in this study (11,12). An analysis
f 129 patients who met MADIT-II study criteria from two
rospective studies found a two-year arrhythmic mortality
ate of 0.0% in those who tested MTWA negative and
and Indeterminate Groups
ICD
rminate
 76)
Negative
(n  75)
Positive
(n  234)
Indeterminate
(n  83)
22.4%) 6 (8.0%) 18 (7.7%) 17 (20.5%)
11.8%) 3 (4.0%) 4 (1.7%) 7 (8.4%)
10.5%) 3 (4.0%) 14 (6.0%) 10 (12.0%)
Adjusted: All Variables
Hazard Ratio (95% CI) p Value
MTWA Positive Versus Negative
2.08 (1.18–3.66) 0.01
2.03 (0.83–4.97) 0.12
1.77 (0.87–3.62) 0.35
TWA Indeterminate Versus Negative
2.78 (1.55–4.99) 0.0006
3.62 (1.44–9.13) 0.006
2.47 (1.17–5.22) 0.018
TWA Positive Versus Indeterminate
0.70 (0.44–1.12) 0.13
0.54 (0.27–1.10) 0.09
0.74 (0.41–1.33) 0.31
ses are depicted. A MTWA positive and indeterminate result were each independent
s in mortality, however, existed between those who tested MTWA positive andative,
ndete
(n
17 (
9 (
8 (
M
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erence5.6% in those who tested non-negative (12). Another
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Prognostic Utility of Microvolt T-Wave Alternans May 2, 2006:1820–7ecent study prospectively followed 177 MADIT-II–
ligible patients for two years and found that those who
ested MTWA non-negative had a hazard ratio of 4.8 (p 
.02 vs. MTWA negative) for all-cause mortality (11). In
hose studies, however, potential differences in baseline
haracteristics between patients with non-negative and neg-
tive MTWA results were not reported or adjusted for
uring statistical analyses (13). Moreover, the mean age of
he study populations was younger (61 and 63 years,
espectively) than that of our study population (67 years).
inally, patients in our study were recruited from an
nselected outpatient population as opposed to a hospital-
zed setting, so there may have been differences in baseline
CD risk between study populations.
A recent meta-analysis of MTWA found that a non-
egative MTWA test result was associated with a univariate
isk ratio for cardiac arrhythmic events of 2.42 (95% CI 1.30
o 4.50) in patients with ischemic cardiomyopathy (14).
owever, the authors reported that the major limitation of
ost studies examining MTWA in various patient popula-
ions has been the lack of adjustment for known risk factors
such as age and LVEF) or other potential confounders.
his has prevented a true assessment of the incremental
rognostic utility of MTWA in predicting mortality
13,14). Moreover, many prior studies have reported cardiac
rrhythmic events as their primary outcome without pro-
iding analyses for all-cause mortality. This leaves open the
ossibility that competing risks (whereby a non-negative
TWA test predicts arrhythmic mortality but not all-cause
ortality) or misclassification bias (for cause-specific mor-
ality) may have confounded earlier results (13). To our
nowledge, our study is the first to assess the prognostic
tility of MTWA for both all-cause and arrhythmic rates of
ortality after adjusting for baseline differences in age and
VEF, as well as for ICD status, medication usage, and
linical variables.
Because of the large sample size in our study, we were
ble to assess whether an MTWA-indeterminate test was
n independent predictor of outcome. Prior studies have
ombined MTWA-positive and -indeterminate patients
nto an MTWA-non-negative category without being able
o adequately assess whether MTWA-indeterminate pa-
ients had similar mortality hazard ratios as MTWA-
ositive patients when compared with MTWA-negative
atients. To our knowledge, our study is the first to
pecifically examine this in patients with ischemic cardio-
yopathy, and we found no significant differences in
ll-cause or cause-specific mortality risks between the
TWA-indeterminate and -positive groups, suggesting
hat our decision to combine them into one “non-negative”
ategory in this study was statistically appropriate. In fact,
he mortality hazard ratio was nonsignificantly higher for
TWA-indeterminate patients than for MTWA-positive
atients. Because the majority of patients (77%) had fre-
uent ectopy or inability to reach adequate heart rate as the
rimary reason for an indeterminate MTWA result, this Tay reflect underlying heart substrates or physical decondi-
ioning that may predispose MTWA-indeterminate pa-
ients to similar or higher mortality rates than MTWA-
ositive patients.
Although our study found that MTWA was an indepen-
ent predictor for all-cause and arrhythmic mortality in the
on-ICD group and for the entire study population, there
ere no significant mortality differences found in the ICD
roup. This is largely because arrhythmic rates of mortality
ere much lower for the ICD group (3.4%) than for the
on-ICD group (7.6%). As a sensitivity test, when a
ombined mortality and appropriate ICD shock end point
as the outcome for the ICD group, a non-negative
TWA was an independent predictor of events (HR 
.42 [95% CI 1.07 to 5.48]). This suggests that patients
ith ICDs who tested MTWA non-negative in our study
ere exposed to higher baseline mortality and arrhythmic
vent rates than those who tested MTWA negative.
The potential implication of MTWA testing in patients
t high risk for SCD is far reaching. The Centers for
edicare and Medicaid Services has recently extended
overage for prophylactic ICD implantation to the SCD-
eFT– and MADIT-II–eligible population (21). How-
ver, this comes at considerable financial cost, and it is likely
hat ICD therapy will continue to be withheld from many
appropriate” candidates because of barriers to treatment,
ncluding lack of hospital and physician resources or a
erception that the existing criteria are too broad (22,23).
he ability to more selectively target devices in high-risk
ndividuals using a screening test such as MTWA might
ead to more complete treatment of those who are most
ikely to benefit (6,24). Our findings raise the possibility
hat, in patients with ischemic cardiomyopathy and without
rior history of ventricular arrhythmia, those who test
TWA non-negative will have a higher absolute and
elative risk of mortality from arrhythmic deaths compared
ith those who test MTWA negative and may therefore
erive more benefit with ICD therapy.
tudy limitations. Our findings should be interpreted in
he context of the following study design issues. First, there
s the potential for residual confounding as with all cohort
tudies. We did not have patient-level data on certain
ariables, including New York Heart Association functional
lass and laboratory data, which may have affected our
esults. A particular strength of our study, however, was our
bility to adjust for ICD status and a number of demo-
raphic, clinical, and treatment variables at a level not
reviously done. Moreover, MTWA can be performed only
n patients with sinus rhythm. This is likely to affect only a
inority of patients, as only 8% to 15% of patients in the
ADIT-II and SCD-HeFT studies were noted to be in
trial fibrillation or atrial flutter.
onclusions. Microvolt T-wave alternans is a strong and
ndependent predictor of all-cause and arrhythmic mortality
n patients with ischemic cardiomyopathy. Microvolt
-wave alternans adds incremental prognostic utility to
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ith significant implications for future risk stratification
odels.
eprint requests and correspondence: Dr. Paul S. Chan, Cardiol-
gy (111-A), VA Ann Arbor Healthcare System, 2215 Fuller Road,
nn Arbor, Michigan 48105. E-mail: paulchan@umich.edu.
EFERENCES
1. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews
ML. Analysis of mortality events in the Multicenter Automatic
Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol
2004;43:1459–65.
2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a
defibrillator in patients with myocardial infarction and reduced ejec-
tion fraction. N Engl J Med 2002;346:877–83.
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable
cardioverter-defibrillator for congestive heart failure. N Engl J Med
2005;352:225–37.
4. Hlatky MA, Sanders GD, Owens DK. Cost-effectiveness of the
implantable cardioverter defibrillator. Card Electrophysiol Rev 2003;
7:479–82.
5. Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness
of prophylactic use of the implantable cardioverter defibrillator or
amiodarone after myocardial infarction. Ann Intern Med 2001;135:
870–83.
6. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky
MA. Effect of risk stratification on cost-effectiveness of the implant-
able cardioverter defibrillator. Am Heart J 2002;144:440–8.
7. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and
economic implications of the Multicenter Automatic Defibrillator
Implantation Trial-II. Ann Intern Med 2005;142:593–600.
8. Lab MJ, Lee JA. Changes in intracellular calcium during mechanical
alternans in isolated ferret ventricular muscle. Circ Res 1990;66:
585–95.
9. Shimizu W, Antzelevitch C. Cellular and ionic basis for T-wave
alternans under long-QT conditions. Circulation 1999;99:1499–507.
0. Armoundas AA, Tomaselli GF, Esperer HD. Pathophysiological basis
and clinical application of T-wave alternans. J Am Coll Cardiol
2002;40:207–17.
1. Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave
alternans distinguishes between patients likely and patients not likely tobenefit from implanted cardiac defibrillator therapy: a solution to the
Multicenter Automatic Defibrillator Implantation Trial (MADIT) II
conundrum. Circulation 2004;110:1885–9.
2. Hohnloser SH, Ikeda T, Bloomfield DM, Dabbous OH, Cohen RJ.
T-wave alternans negative coronary patients with low ejection and
benefit from defibrillator implantation. Lancet 2003;362:125–6.
3. Chan PS, Nallamothu BK, Chow T. Microvolt T-wave alternans:
where do we go from here (letter to the editor)? J Am Coll Cardiol
2006;47:1736.
4. Gehi AK, Stein RH, Metz LD, Gomes JA. Microvolt T-wave
alternans for the risk stratification of ventricular tachyarrhythmic
events: a meta-analysis. J Am Coll Cardiol 2005;46:75–82.
5. Bloomfield D, Hohnloser S, Cohen R. Interpretation and classifica-
tion of microvolt T wave alternans tests. J Cardiovasc Electrophysiol
2002;13:502–12.
6. Hohnloser SH, Klingenheben T, Bloomfield D, Dabbous O, Cohen
RJ. Usefulness of microvolt T-wave alternans for prediction of ven-
tricular tachyarrhythmic events in patients with dilated cardiomyopa-
thy: results from a prospective observational study. J Am Coll Cardiol
2003;41:2220–4.
7. Hinkle LE, Jr., Thaler HT. Clinical classification of cardiac deaths.
Circulation 1982;65:457–64.
8. Chan PS, Hayward RA. Mortality reduction by implantable
cardioverter-defibrillators in high-risk patients with heart failure,
ischemic heart disease, and new-onset ventricular arrhythmia: an
effectiveness study. J Am Coll Cardiol 2005;45:1474–81.
9. National Death Index User’s Manual. Hyattsville, MD: Department
of Vital Statistics, Centers for Disease Control, 2003.
0. Hosmer D, Lemeshow S. Applied Survival Analysis: Regression
Modeling of Time to Event Data. New York, NY: John Wiley &
Sons, 1999:241–70.
1. Phurrough S, Salive M, Baldwin J, Chin J. Decision Summary: Implant-
able Cardioverter-Defibrillators (CAG 00157R2). Available at:
http://www.cms.hhs.gov/mcd/viewncd.asp?ncd_id20.4&ncd_version
2&basketncd:20.4:2:ImplantableAutomaticDefibrillators.
Accessed December 28, 2004.
2. Buxton AE. Risk stratification for sudden death: do we need anything
more than ejection fraction? Card Electrophysiol Rev 2003;7:434–7.
3. Buxton AE. The clinical use of implantable cardioverter defibrillators:
Where are we now? Where should we go? Ann Intern Med 2003;138:
512–4.
4. Kent DM, Hayward RA, Griffith JL, et al. An independently derived
and validated predictive model for selecting patients with myocardial
infarction who are likely to benefit from tissue plasminogen activator
compared with streptokinase. Am J Med 2002;113:104–11.
